

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Akums launches novel Combikit for treatment of Duodenal Ulcer and H. pylori infection

26 April 2023 | News

In India, there are a large number of patients that suffer from duodenal ulcer and H pylori infection



New Delhi-based Akums Drugs and Pharmaceutical has announced the launch of its latest formulation, a unique Combikit – (Amoxicillin + Clarithromycin + Esomeprazole). This Combikit is the first of its kind to be introduced in India by Akums.

Combikit (Amoxicillin + Clarithromycin + Esomeprazole) is approved by the Central Drugs Standard Control Organisation (CDSCO) for the healing of duodenal ulcers associated with *Helicobacter pylori* (*H. pylori*) and eradication of *H. pylori* in patients with active or healed peptic ulcer.

The *H. pylori* eradication therapy has shown efficacy in reducing the risk of ulcer recurrence, providing a great benefit for patients. *H. pylori* is a very common infection in India, implicated in the etiology of gastritis and peptic ulcers in humans.

This Combikit is a combination of three effective drugs - Amoxicillin, Clarithromycin, and Esomeprazole. This combination works by inhibiting the growth of *H. pylori* bacteria and reducing the production of gastric acid. The drug is available in a patient convenient pack, for a complete course of therapy.